Evidence map›Paper›PMID 37178117›Full record

ArticleCell reports2023

Tumor eradication by hetIL-15 locoregional therapy correlates with an induced intratumoral CD103

Dimitris Stellas, Sevasti Karaliota, Vasiliki Stravokefalou, Matthew Angel, Bethany A Nagy, Katherine C Goldfarbmuren, Cristina Bergamaschi, Barbara K Felber, George N Pavlakis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Dimitris StellasHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA; Department of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece. Electronic address: george.pavlakis@nih.gov.
Sevasti KaraliotaHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Vasiliki StravokefalouHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA; Department of Pharmacology, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.
Matthew AngelVaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Bethany A NagyLaboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Katherine C GoldfarbmurenVaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Cristina BergamaschiHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA.
Barbara K FelberHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA.
George N PavlakisHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA. Electronic address: george.pavlakis@nih.gov.
Leidos (United States) · USFrederick National Laboratory for Cancer Research · USNational Hellenic Research Foundation · GRUniversity of Thessaly · GR

Funding

Heterodimeric IL-15 in Cancer ImmunotherapyZIABC010750 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2009 to 2022
$15.6M
Examining IL-15 as an immunotherapy agent in cancer and AIDSZIABC012105 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FELBER, BARBARA K · 2022 to 2025
$5.3M
Intramural NIH HHS ZIA BC010750Intramural NIH HHS ZIA BC012105
6 · The paper itself

Abstract

Locoregional monotherapy with heterodimeric interleukin (IL)-15 (hetIL-15) in a triple-negative breast cancer (TNBC) orthotopic mouse model resulted in tumor eradication in 40% of treated mice, reduction of metastasis, and induction of immunological memory against breast cancer cells. hetIL-15 re-shaped the tumor microenvironment by promoting the intratumoral accumulation of cytotoxic lymphocytes, conventional type 1 dendritic cells (cDC1s), and a dendritic cell (DC) population expressing both CD103 and CD11b markers. These CD103

Indexed as

Antineoplastic AgentsNeoplasmsAnimalsCytokinesDendritic CellsImmunologic FactorsIntegrin alpha ChainsLymphocytesMiceMice, Inbred C57BLTumor MicroenvironmentAntineoplastic AgentsCytokinesImmunologic FactorsIntegrin alpha Chainsbreast cancerCP: CancerCP: Immunologycytokinesdendritic cellsIL-15immonotherapyinterleukin-15mouse modelsT cell memory

Identifiers

PMID37178117
PMCPMC10758290
OpenAlexW4376269757

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.